If you or a loved one is taking Tysabri, you may be wondering how doctors monitor for the rare brain infection PML and what the test results really mean. Decades of pharmacovigilance and clinical research have established a structured approach to risk surveillance. This page summarizes the evidence on monitoring tests and follow-up, clarifying what current science can and cannot confirm.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Pennsylvania who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations, including the statute of limitations, is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, and patients must be enrolled in the restricted TOUCH Prescribing Program to ensure monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically presents with progressive neurological deficits such as weakness, visual changes, cognitive decline, or coordination problems. Diagnosis is confirmed by brain MRI and detection of JC virus DNA in cerebrospinal fluid.
The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can allow latent JC virus to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination. The timeline between exposure and documented harm varies; PML can occur after a few months to several years of treatment, with risk increasing significantly after 24 months of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For affected patients in Pennsylvania, settlement-related considerations depend on the adequacy of warnings provided by the manufacturer. The boxed warning explicitly states that healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML and withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether prescribers and patients were adequately informed about the specific risk factors and the need for vigilant monitoring. The TOUCH program requires patients to read a Medication Guide and understand the risks, but the effectiveness of these measures in preventing PML is limited by the unpredictable nature of JC virus reactivation.
The statute of limitations for filing a Tysabri-related PML lawsuit in Pennsylvania is generally two years from the date the injury was discovered or reasonably should have been discovered. This discovery rule means the clock starts when the patient or their family becomes aware of the link between Tysabri and PML, not necessarily when the drug was first taken. Given that PML symptoms can be subtle and initially mistaken for multiple sclerosis relapse, the date of diagnosis is often the key trigger. Patients who received Tysabri and later developed PML should consult with legal counsel promptly to assess their individual timeline. Settlement amounts for PML cases can vary widely based on factors such as the severity of disability, medical expenses, lost income, and the strength of evidence regarding inadequate warnings. The documented harm from PML is severe, with most patients experiencing permanent neurological deficits or death. The risk-benefit analysis for Tysabri requires careful consideration, as the drug provides significant benefit for many patients with relapsing multiple sclerosis, but the PML risk is a serious adverse effect that must be managed through strict monitoring protocols.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Pennsylvania, the statute of limitations for filing a Tysabri-related PML lawsuit is generally two years from the date the injury was discovered or reasonably should have been discovered. This discovery rule means the clock starts when the patient or their family becomes aware of the link between Tysabri and PML, not necessarily when the drug was first taken. Given that PML symptoms can be subtle and initially mistaken for multiple sclerosis relapse, the date of diagnosis is often the key trigger. Patients should consult with legal counsel promptly to assess their individual timeline.
Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, and patients must be enrolled in the restricted TOUCH Prescribing Program to ensure monitoring.
PML typically presents with progressive neurological deficits such as weakness, visual changes, cognitive decline, or coordination problems. Diagnosis is confirmed by brain MRI and detection of JC virus DNA in cerebrospinal fluid. The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.